iBB
46.4K views | +5 today
Follow
iBB
Institute for Bioengineering and Biosciences
Curated by iBB
Your new post is loading...
Your new post is loading...
Scoop.it!

Cátia Bandeiras to Defend PhD Thesis in Bioengineering

Cátia Bandeiras to Defend PhD Thesis in Bioengineering | iBB | Scoop.it

Cátia Filipa Medina Bandeiras will be defending her PhD thesis in Bioengineering (MIT Portugal Program) on Friday the 8th November 2019 (14 H, amphitheater PA-3, Mathematics Building). During the last years, and under the supervision of Frederico Ferreira from SCERG and BERG-IBB and Stan Finkelstein from MIT, Cátia developed an open-source framework for combined bioprocess and health economics modeling, aiming at the evaluation of stem cell engineering innovations towards the commercialization of stem cell-based therapies. She used this framework to evaluate the impact of manufacturing component choices, like culture media and expansion technologies, the scale of manufacturing, and the long-term cost-effectiveness of stem cell-based therapies for type 1 diabetes and cystic fibrosis. This computational approach, based on experimental data, provided cues for additional reductions in the cost of goods, and recommendations for precision medicine of these prospective therapies. The title of the thesis is “TESSEE – Tool for Early Stem Cells Economic Evaluation”

No comment yet.
Scoop.it!

Towards Cost-effective Stem Cell-based Therapies for Type 1 Diabetes

Towards Cost-effective Stem Cell-based Therapies for Type 1 Diabetes | iBB | Scoop.it

Type 1 diabetes is an auto-immune disease where patients need to monitor and take insulin daily. Transplantation of encapsulated islet cells is performed in some countries to restore glucose control, but shortage of donors is a major bottleneck. Devices with stem cell-derived beta cells are now in clinical trials. Researchers at SCERG-iBB and Harvard Medical School performed an early health technology assessment modeling study to simulate, based on bioprocess and disease progression modeling, the manufacturing costs of devices containing pluripotent stem cell (PSC)-derived beta cells. This information was combined with medical data to determine cost-effectiveness of the new therapy. The work was published in Biotechnology Journal.

No comment yet.